Last week our researchers and physicians discussed a paper about AHSCT compared to Lemtrada to treat RRMS. Autologous hematopoietic stem cell transplantation (AHSCT), a different stem cell therapy than the one used at IMSMP, was compared to Lemtrada in an observational study for safety and efficacy...
Happy Thanksgiving from everyone at Tisch MSRCNY! Our office will be closed for the holiday beginning on Wednesday, November 25th at 1:30pm and will reopen on Monday, November 30th at 9:00 AM. Wishing everyone a safe and happy holiday!
*/ *|MC_PREVIEW_TEXT|* We Have The Scientists . . . A Special Introduction from Dr. Saud A. Sadiq Dr. Saud A. Sadiq, Director and Chief Research Scientist of Tisch MS Research Center of New York invites you to learn more about our cutting-edge investigations into the cause and cure of MS. He will...
In our Phase I two-year follow up study, our clinical team monitored the Phase I patients for two additional years after their treatment. Our results showed that there were no long-term side effects from the MSC-NP therapy. Importantly, a subset of patients showed sustained clinical improvement two...
Merry Christmas from all of us at the Tisch MSRCNY! Our office will be closed for the holiday beginning on Wednesday, December 23rd at 3:00pm and will reopen on Monday, December 28th at 9:00 AM. A neurologist is on-call and may be reached at (212) 265-8070 for any MS-related emergencies. Wishing a...
June 12, 2020: At Journal Club, our experts sat down to discuss a paper on a new method for purifying astrocytes derived from stem cells. CD49f Is a Novel Marker of Functional and Reactive Human iPSC-Derived Astrocytes Astrocytes are a type of cell in the central nervous system that play an...